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Summary TA01 (molecular weight 35.0 kDa, isoelectric point 5.45) and TA02 (molecularweight 35.0 kDa, isoelectric point 5.29) polypeptides
were detected using two-dimensional polyacrylamide gel electrophoresis (2-DE). A previous study has shown that these polypeptides are
distributed in primary adenocarcinomas and some large - cell carcinomas of the lung. However, various expression levels of TA01 and TA02
polypeptides were demonstrated in adenocarcinoma, while large-cell carcinoma expressed low levels. To evaluate the relationship between
the expression of TA01 and TA02 polypeptides and the histocytological features of primary adenocarcinoma of the lung, these two
polypeptides were analysed by 2-DE combined with a non-enzymatic sample preparation technique, and their expression levels were
compared with the histocytological features of primary lung adenocarcinoma. Out of 57 primary lung adenocarcinoma cases, 46 cases
(80.7%) and 52 cases (91.2%) expressed TA01 and TA02 polypeptides respectively. Furthermore, the expression levels of TA01 and TA02
polypeptides correlated with the degree of cellular atypia, structural atypia and histocytological differentiation of primary lung
adenocarcinoma. On the other hand, these two polypeptides were not detected in adenocarcinoma of the lung, metastatic from the colon and
mammary glands. High expression of TA01 and TA02 polypeptides reflected the differentiation of primary adenocarcinoma in the lung. These
two polypeptides are valuable in determining the histocytological differentiation of primary lung adenocarcinoma as well as in distinguishing
between primary and metastatic adenocarcinoma of the lung.
Keywords: primary adenocarcinoma of the lung; histopathological differentiation; TA01 polypeptide; TA02 polypeptide; two-dimensional
polyacrylamide gel electrophoresis
Tumour markers can contribute to clinicopathological diagnosis,
more accurate evaluation of biological malignancy of the tumour
and selection of therapeutic strategy. Products of oncogenes and
mutant tumour-suppressor genes are possible candidates for
biological tumour markers. Also, histological differentiation anti-
gens could be useful markers in cases ofborderline histology.
Although some tumour markers (e.g. CEA, CA 19-9 and TPA,
etc.) are used in the clinical diagnosis ofprimary adenocarcinoma
ofthe lung (Vincent et al, 1979; Latanche et al, 1985; Buccheri et
al, 1988; Niklinski et al, 1995), there is no specific tumour marker
forprimary adenocarcinoma ofthe lung. At present, cell prolifera-
tion and products of oncogenes and tumour-suppressor genes in
lung adenocarcinoma are attracting attention (M0rkve et al, 1992;
Scagliotti etal, 1993; Ebina etal, 1994; Rachwal et al, 1995; Costa
et al, 1996) as biological tumour markers. In addition, histological
differentiation antigens have been investigated. Non-ciliated, non-
mucous cells in the bronchioles (Clara cells) and type II alveolar
epithelial cells in the alveolar sac, where primary adenocarcinoma
of the lung originates, express surfactant apoprotein A (Auten et
al, 1990), Clara cell-specific 10-kDa protein (Singh et al, 1990;
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Linnoila et al, 1992) and protein 1 (Barnard et al, 1992). There is a
possibility that these polypeptides become specific tumour
markers for primary adenocarcinoma of the lung. Such a marker
might be useful to distinguish primary and metastatic adenocarci-
noma ofthe lung.
We also investigated tumourpolypeptides using the two-dimen-
sional polyacrylamide gel electrophoresis (2-DE) technique
(O'Farrell, 1975) and clinical tumour materials in an attempt to
discover useful tumour markers. Recently, we reported that there
were some characteristic 2-DE patterns for each histological type
ofprimary lung carcinoma and that TA0I polypeptides (MW 35.0
kDa, pI 5.45) and TA02 polypeptides (MW 35.0 kDa, pl 5.29) that
are related to primary adenocarcinoma of the lung can be identi-
fied (Okuzawa et al, 1994; Hirano etal, 1995).These two polypep-
tides were expressed in most primary adenocarcinomas and some
large-cell carcinomas of the lung, but the other histological types
of primary lung carcinoma and metastatic lung adenocarcinoma
from the colon and rectum did not express TAO1 and TA02
polypeptides. Also, in breast carcinoma the expression levels were
very low or undetectable (22.7% in TAO1 polypeptide, 4.3% in
TA02 polypeptide) (Hirano et al, 1995). In the case of primary
adenocarcinoma of the lung, the range of expression levels of
TAO1 and TA02 polypeptides was wide.
We describe the relationship between the expression levels of
TAO1 and TA02 polypeptides and the histocytological features of
primary adenocarcinoma of the lung. Furthermore, the possibility
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of using these two polypeptides as differentiation markers for
primary adenocarcinoma ofthe lung is discussed.
MATERIALS AND METHODS
Histocytological specimens and 2-DE materials from
clinical tumours
Clinical materials for 2-DE were obtained from 109 patients with
primary lung carcinoma, resected at the Department of Surgery,
Tokyo Medical College Hospital from December 1993 to
November 1995. Pathologically, these cases were diagnosed as 57
cases of adenocarcinoma. There were 23 cases of well-differenti-
ated adenocarcinoma (WD adenocarcinoma), 14 cases of moder-
ately differentiated adenocarcinoma (MD adenocarcinoma), 20
cases of poorly differentiated adenocarcinoma (PD adenocarci-
noma), 23 cases of squamous cell carcinoma, three cases of
adenosquamous cell carcinoma, five cases oflarge-cell carcinoma,
one case of undifferentiated carcinoma, nine cases of small-cell
carcinoma and four cases of carcinoid tumour. Additionally, we
analysed metastatic lung carcinoma materials (six cases of
metastatic lung carcinoma from the colon and one case of
metastatic lung carcinoma from the mammary glands). Further-
more, in cases of adenocarcinoma, cellular atypia and structural
atypia were classified as low, intermediate and high grade by
microscopical observation ofhistopathological specimens.
Whenpositive findings ofAlcian blue andperiodic acid - Schiff
(PAS) staining was observed in poorly differentiated cases, our
pathologists diagnosed these cases as PD-adenocarcinoma. The
cases with negative Alcian blue and PAS staining werejudged as
large-cell carcinoma.
In 38 cases out of 57 cases of adenocarcinoma, brushing
cytology specimens or needle cytology specimens were available
for study. These cytological materials were obtained before any
treatment, and these specimens were stained using the
Papanicolaou method.
For the purpose of this study two cytologists and two patholo-
gists independently re-examined histocytological features of all
cases.
Non-enzymatic sample preparation from the resected
tumours and two-dimensional polyacrylamide gel
electrophoresis
The 2-DE combined non-enzymatic sample preparation technique
was performed according to our previous descriptions (Franzen et
al, 1994; Okuzawa et al, 1994)
Tumour cell-rich materials were obtained after scraping the
tumour surface with a scalpel,filtration, selection ofviable tumour
cells using 54.7% Percoll solution (specific gravity = 1.07) and
washing in phosphate-buffered saline. Tumour cells were broken
by repeatedly freezing and thawing, and then soluble fractions
were lyophilized after adding DNAase - RNAase. The materials
were resolubilized using a sample buffer containing a high
concentration of urea, NP-40 and 3-[(3-cholamidopropyl) di-
methylammonio]-l-propanesulphonate (CHAPS). In the 2-DE
technique, isoelectric focusing (IEF) was used in the first dimen-
sion followed by sodium dodecyl sulphate (SDS) polyacrylamide
gel electrophoresis. A sample corresponding to 30 Rg of protein
was applied to IEF tubes and focused for 14.5 h at 800 V and for
1 h at 1000 V using a Protein II cell (Bio-Rad) and Model
1000/500 Power Supply (Bio-Rad). After IEF, IEF gels were set
on top of a linear gradient 10-13% SDS polyacrylamide gel and
electrophoresed overnight using 10 mA per gel at 10°C. After
protein fixation, proteins were visualized by silver staining
(Morrissey, 1981).
Identification of known polypeptides and evaluation of
expression level of TA01 and TA02 polypeptides
Some human polypeptides were identified on the 2-DE gel by
comparison of our 2-DE patterns and previously published 2-DE
maps (Ochs et al, 1981; Garrels et al, 1989; Bhattacharya et al,
1990; Celis et al, 1992; Bjellqvist et al, 1994). Furthermore, co-
electrophoresis of purified polypeptides and subcellular fractions,
as well as samples characterized from other laboratories, was very
useful for identification ofhuman polypeptides.
Based on these data,TAO1 andTA02 polypeptides were detected
as unidentified polypeptides, and their molecular weights and
isoelectric points werecalculated (Hirano etal, 1995).Furthermore,
we evaluated the expression level ofTAO1 and TA02 polypeptides
as high expression (++), intermediate expression (+), low expres-
sion (±) orundetectable level (-) according to the intensity ofsilver
staining. Spots evaluated as a high level of expression (++) were
more than 3 mm in diameter, sometimes accompanied by a small
tail towards the high molecular weight side. Spots indicating inter-
mediate level expression (+) were less than 3 mm in diameter and
were clearly recognized as round black spots. Faint grey spots were
interpreted to indicate a low level ofexpression (±).
Evaluation of the relationship between 2-DE findings
and histocytological features
We attempted to evaluate the relationship between the expression
levels of these two polypeptides on 2-DE gels and the histocyto-
logical features ofadenocarcinoma. We mainly evaluated morpho-
logical formation of cellular clusters, cytoplasmic features and
Table 1 Relationship between expression of TA01 and TA02 polypeptides
and histopathological types of lung carcinoma
_ - + ++
TA01 polypeptide
Adenocarcinoma 11 17 13 16
Squamous cell carcinoma 23 0 0 0
Adenosquamous cell carcinoma 1 2 0 0
Large-cell carcinoma 2 3 0 0
Undifferentiated carcinoma 1 0 0 0
Small-cell carcinoma 9 0 0 0
Carcinoid tumour 4 0 0 0
Metastatic lung adenocarcinoma 7 0 0 0
TA02polypeptide
Adenocarcinoma 5 14 16 22
Squamous cell carcinoma 23 0 0 0
Adenosquamous cell carcinoma 1 2 0 0
Large-cell carcinoma 2 3 0 0
Undifferentiated carcinoma 1 0 0 0
Small-cell carcinoma 9 0 0 0
Carcinoid tumour 3 1 0 0
Metastatic lung adenocarcinoma 7 0 0 0
-, undetectable; ±, low expression; +, intermediate expression; ++, high
expression.
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Figure 1 Overview of the 2-DE pattern of WD-adenocarcinoma of the lung.
The regions shown in Figure 2 are enclosed by boxes
nuclear chromatin patterns in cytological specimens. Only
brushing cytology specimens or needle cytology specimens
obtained before any treatment were considered suitable for this
study to limit the material to non-degenerated cancer cells
obtained directly from the main lesion. Cytological specimens
were available in 38 out of 57 adenocarcinoma cases.
Furthermore, in histological specimens that were obtained after
surgery, the relationships between the expression levels of TAOI1
and TA02 polypeptides and some histopathological factors [e.g.
cellular atypia, structural changes associated with atypia (struc-
tural atypia) and histopathological differentiation] were evaluated.
Statistical evaluation
Statistical analysis ofdata was performed using the chi-square test.
Differences were considered significant when the P-value was less
than 0.051.
RESULTS
In no case of squamous cell carcinoma, small-cell carcinoma or
undifferentiated carcinoma were TAOI and TA02 polypeptides
detected. However, TAO and TA02 polypeptides were detected in
46 cases (80.7%) and 52 cases (91.2%) out of 57 adenocarcinoma
cases respectively. Low expression of both TA01 and TA02
polypeptides was observed in 66.7% ofadenosquamous cell carci-
noma and 60.0% of large-cell carcinoma. One case of carcinoid
tumour showed very low expression of TAo2 polypeptides.
Furthermore, no metastatic carcinomas ofthe lung expressed these
two polypeptides (Table 1)s
Figure 1 shows an overview of the representative 2-DE pattern
of a well-differentiated adenocarcinoma. The regions shown in
Table 2 Relationship between expression of TAOI and TA02 polypeptides
and cellular atypia
± + ++
TA01 polypeptide
Low-grade atypia 1 0 1 7
Intermediate-grade atypia 1 5 12 8
High-grade atypia 9 12 0 1
TA02polypeptide
Low-grade atypia 1 0 0 8
Intermediate-grade atypia 1 1 11 13
High-grade atypia 3 13 5 1
See Table 1 for explanation of expression levels. TA01, P< 0.000001; TA02,
P= 0.000043.
Table 3 Relationship between expression of TA01 and TA02 polypeptides
and structural atypia
± + ++
TA01 polypeptide
Low-grade atypia 1 1 8 12
Intermediate-grade atypia 1 5 4 4
High-grade atypia 9 11 1 0
TA02polypeptide
Low-grade atypia 1 2 2 17
Intermediate-grade atypia 2 0 7 5
High-grade atypia 2 12 7 0
See Table 1 for explanation of expression levels. TA01, P= 0.000006; TA02,
P = 0.000001.
Table 4 Relationship between expression of TA01 and TA02 polypeptides
and histopathological differentiation
_ + ++
TA01 polypeptide
WD 2 1 8 12
MD 0 5 5 4
PD 9 11 0 0)
TA02polypeptide
WD 2 1 3 17
MD 1 2 6 5
PD 2 11 7 0
See Table 1 for explanation of expression levels. WD, well-differentiated
adenocarcinoma; MD, moderatly differentiated adenocarcinoma; PD, poorly
differentiated adenocarcinoma. TA01, P = 0.000001; TA02, P= 0.000031.
Figures 2, 3 and 4 are enclosed by boxes in Figure 1. 2-DE find-
ings, cytological features and histopathological features of repre-
sentative primary lung adenocarcinoma cases with various
expression levels of TAO1 and TA02 polypeptides are shown in
Figure 2 and 3. Also, 2-DE findings of representative cases with
metastatic adenocarcinoma ofthe lung are shown in Figure 4.
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Figure 3 2-DE findings (A), cytological features (B) and histopathological features (C) of two cases ofgoblet cell-type primary adenocarcinoma of the lung. O, TA01 polypeptide; 0 TA02 polypeptide. Original magnification: cytological features xl000, histopathological features x200. Although these two cases were
diagnosed as WD-adenocarcinoma, both TA01 and TA02 polypeptides were not detected on 2-DE gels
A
Figure 4 2DE-findings of representative cases with metastatic lung
adenocarcinoma 0, TA01 polypeptide; 0, TA02 polypeptide. A, metastatic
lung carcinoma from the colon; B, metastatic lung carcinoma from mammary
glands. All seven cases with metastatic lung adenocarcinoma that we
investigated showed an undetectable level of TA01 and TA02 polypeptides
on 2-DE gels
The relationship between the expression levels of TAO1
and TA02 and cytological findings in adenocarcinoma
The adenocarcinoma cases with high expression of TAOI and
TA02 polypeptides showed papillary clusters or compact clusters
accompanied by cellular overlapping, a weak tendency towards
difference in cancer cell size, round nuclei and finely granular
nuclearchromatin patterns. Furthermore, solitary cancercells were
infrequently observed. These are typical findings of primary
adenocarcinoma of the lung, including bronchioloalveolar cell
carcinoma. (Figure 2, case 1 and case 2)
In cases with either low expression or undetectable levels of
these polypeptides, cell-to-cell adhesion was not tight, even
though papillary cellular clusters were observed. Furthermore,
thickening of the nuclear margin, remarkable difference in
cancerous cell size, polygonal shape in nuclei and coarsely gran-
ular nuclear chromatin patterns were observed in these cases.
Cases with undetectable levels of TAO1 and TA02 polypeptides
frequently showed solitary cancer cells with a very coarse chro-
matin pattern. It was difficult to preoperatively diagnose such
cases as adenocarcinoma on the basis of cytological specimens.
(Figure 2, case 5 and case 6)
Relationship between the expression levels of TAO1
and TA02 polypeptides and histopathological findings
of adenocarcinoma
Table 2 shows the relationship between the expression levels of
TAOl and TA02 polypeptides and cellular atypia using histopatho-
logical specimens. Seven out of nine cases that were evaluated as
low-grade cellular atypia revealed high expression of TAO1
polypeptide. Also, eight out of nine cases with low-grade cellular
atypia revealed high expression of TA02 polypeptide. The only
case with low-grade atypia that had undetectable levels of TAOI
and TA02 polypeptides was one of the two cases diagnosed
histopathologically as goblet cell-type adenocarcinoma (Figure 3).
On the other hand, most cases with high-grade cellular atypia
showed either low expression or undetectable levels of these two
polypeptides.
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There was a statistically significant relationship between
expression levels of TAO1 and TA02 polypeptides and cellular
atypia (TAO1, P < 0.000001; TA02, P = 0.000043).
Table 3 shows the relationship between the expression levels of
TAO1 and TA02 polypeptides and histological structural changes
associated with atypia (structural atypia). Twenty-two cases were
judged to have low-grade structural atypia, and 12 cases and 17
cases out of the 22 cases showed high expression of TAO1 and
TA02 polypeptides respectively. Twenty out of twenty-one cases
judged as high-grade structural atypia showed either low expres-
sion or an undetectable level ofTAO1 polypeptide. Also, 14 cases
out ofthe 21 cases with high-grade structural atypia showed either
low expression or an undetectable level ofTA02 polypeptide.
A statistically significant relationship between expression levels
of TAO1 and TA02 polypeptides and structural atypia was recog-
nized. (TAO1, P = 0.000006; TA02, P = 0.000001)
Table 4 shows the relationship between the expression levels of
TAO1 and TA02 polypeptides and histopathological differentia-
tion. Seventeen out of twenty-three cases with WD adenocarci-
noma showed high expression of either TAO1 or TA02
polypeptides. On the other hand, no PD adenocarcinoma showed
high expression ofTA01 and TA02 polypeptides.
Most cases with high expression of both TAO1 and TA02
polypeptides showed a growth pattern in which normal alveolar
cells were replaced with cancer cells and in which the normal
alveolar structure was well preserved (Figure 2, case 1 and case
2). Such a growth pattern, resembling bronchioloalveolar cell
carcinoma, could be observed in peripheral areas of the tumour
with high expression ofTA01 and TA02 polypeptides. In contrast,
this growth pattern was not observed in any regions ofthe tumour
with either low expression or an undetectable level of these
two polypeptides, except for two cases ofgoblet cell - type adeno-
carcinoma.
Levels ofTAO1 and TA02 polypeptides were undetectable in 11
and 5 cases, respectively, out of a total of 57 primary lung adeno-
carcinoma. Thirteen cases had an undetectable level of one TA
polypeptide and a low expression level ofthe other. These 13 cases
consisted of 12 cases of PD adenocarcinoma and one case of MD
adenocarcinoma containing a squamous component. Three cases
expressed neither of the TA-polypeptides, and we judged
histopathologically that one case was PD adenocarcinoma and that
the remaining two cases were WD adenocarcinoma and goblet cell
type. These were the only two cases diagnosed as goblet cell type
among the 57 cases with primary adenocarcinoma ofthe lung that
we analysed in this study.
There was a statistically significant relationship between
expression levels ofTAO1 and TA02 polypeptides and histopatho-
logical differentiation. (TAO1, P=0.000001; TA02, P=0.000031)
DISCUSSION
The classification ofprimary lung carcinoma has been established
based on morphology (WHO, 1981; Mountain, 1986; Addis,
1988). However, histologically borderline cases of primary lung
carcinoma have been reported (e.g. non-small-cell lung carcinoma
accompanied by neuroendocrine features, small-cell lung carci-
noma with a large-cell component, etc.) (Radice et al, 1982;
Nomori et al, 1986; Gazdar and Linnoila, 1988; Hirsh et al, 1988).
It is very difficult to evaluate some borderline cases based only on
histopathological features. It is hoped that biological tumour
markers could be used to complement morphological diagnosis.
Several kinds of neuroendocrine markers [e.g. neuron-specific
enolase (NSE), gastrin-releasing peptide (GRP), creatine kinase
BB, neural cell adhesion molecule (NCAM), etc.] are useful to
distinguish small-cell lung cancer from non-small-cell lung cancer
(Gazdar et al, 1981; Camey et al, 1982; Maruno et al, 1989;
Kibbelaar et al, 1991). Non-small-cell lung cancer is a heteroge-
neous group oftumours including adenocarcinoma, squamous cell
carcinoma and large-cell carcinoma, and each histopathological
type of tumour displays a characteristic marker pattern. However,
no current tumour markers for non-small-cell lung cancer,
including adenocarcinoma, give us satisfaction in terms of either
sensitivity or specificity.
In this context, we recently showed using 2-DE the possibility
that primary lung carcinoma could be evaluated based on the
expression levels of several kinds of unidentified polypeptides
associated with histopathological differentiation. (Hirano et al,
1995). We believe that this classification of primary lung carci-
noma, based on 2-DE findings, in combination with morpholog-
ical features reflects the biological features of the tumour more
accurately than morphological features alone. TAO1 and TA02
polypeptides occupied an important position in our previous
analysis because these two polypeptides were representatively
associated with primary adenocarcinoma ofthe lung. Furthermore,
TAO1 and TA02 polypeptides showed the highest expression
levels on 2-DE gels ofmost WD adenocarcinomas, and metastatic
lung adenocarcinomas from the colon and most breast carcinomas
did not express either ofthese two polypeptides. Therefore, in this
study, we concentrated on the analysis oftherelationships between
the expression levels of these two polypeptides and histocytolog-
ical features ofprimary adenocarcinoma ofthe lung.
We developed a non-enzymatic sample preparation technique
for removal of serum proteins, necrosis, mesenchymal cells and
inflammatory cells (Franzen et al, 1994; Okuzawa et al, 1994;).
This unique sample preparation technique enabled both high-reso-
lutional 2-DE analysis of clinical materials and accurate analysis
of cancer proteins. When the lysate of whole tumour tissues was
used as samples for 2-DE without using our sample preparation
methods, there were many changes in the 2-DE patterns, e.g.
increase of expression levels of all tropomyosin isoforms, which
normal cells express, and decrease in expression levels of TAO1
and TA02 polypeptides. These findings show that cancerous cells
of primary adenocarcinoma of the lung themselves produced
TAO1 and TA02 polypeptides. We think that the decrease in
expression levels ofTAO1 and TA02 polypeptides was because of
contamination and dilution by several kinds ofnormal cells.
Most cases with high expression of TAO1 and TA02 polypep-
tides were diagnosed as WD adenocarcinoma cytologically and
histologically. On the other hand, most cases with low expression
of these polypeptides showed high cellular and structural atypia
and were diagnosed as either PD or MD adenocarcinoma. Further-
more, it was difficult to preoperatively diagnose cytological speci-
mens of some cases with undetectable levels of either TAO1 and
TA02 polypeptides as adenocarcinomas.
We concluded that TAO1 and TA02 polypeptides are related to
histopathological differentiation ofprimary lung adenocarcinoma.
Cases with high expression of TAO1 and TA02 polypeptides
showed a growth pattern resembling bronchioloalveolar cell carci-
noma at least in a part ofthe tumour (especially in peripheral areas
of tumour). Although only 2 out of 23 cases diagnosed as WD
adenocarcinoma had undetectable levels of both TAO1 and TA02
polypeptides, detailed histopathological examination of these two
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cases revealed goblet cell type ofadenocarcinoma (Figure 3). This
type of adenocarcinoma derives from the mucous cells that
distribute in relatively peripheral bronchi and not in the alveolar
region. With respect to the cells oforigin of cancer cells with high
expression ofTAOI and TA02 polypeptides, it was suggested that
these two polypeptides accumulated in type II pneumocytes of the
alveolar sac and/or non-ciliated non-mucous cells in the bronchi-
oles (Clara cells) where mostprimary adenocarcinomas ofthe lung
originate. However, at present, we do not have any direct evidence
of the cellular distribution of these two polypeptides in normal
tissues because the resolution of 2-DE is very low in normal
peripheral lung tissues. Production of antibodies against these
polypeptides is needed for further investigation. Recently, we
obtained mouse polyclonal antibody against TA02 polypeptide by
subcutaneous injection of TA02 polypeptide. According to our
preliminary data using this polyclonal antibody, TA02 polypeptide
is distributed in the cell membrane and cytoplasm ofprimary lung
adenocarcinomas, in particular WD adenocarcinomas. Also, the
cell membrane and cytoplasm of part of the alveolar epithelium
(probably type II pneumocyte) revealed positive staining (data not
shown). At present, we are trying to produce the monoclonal anti-
bodies for further investigation ofthese molecules.
It would be reasonable that the distribution of these two
polypeptides in cancer tissues compared with that of known
polypeptides would resemble that of surfactant apoprotein A,
Clara cell-specific 10-kDa protein and protein 1 in primary lung
carcinoma (Singh et al, 1988; Auten et al, 1990; Barnard et al,
1992; Linnoila et al, 1992). The molecular weights of Clara cell-
specific 10-kDa protein and protein 1 are completely different
from those ofTAO1 and TA02 polypeptides. However, the molec-
ular weight of surfactant apoprotein A (35-37 kDa) is approxi-
mately that of TAO1 and TA02 polypeptides. Therefore, we
attempted to detect TAO1 and TA02 polypeptide using anti-surfac-
tant apoprotein A monoclonal antibody (PE-1, DAKO) after 2-DE
and Western blotting in cases with high expression of TAO1 and
TA02 polypeptides. However, these two polypeptides could not be
detected by the PE-1 monoclonal antibody (data not shown).
In the cases with high expression of TAO1 and TA02 polypep-
tides, we detected a third polypeptide with the same molecular
weight. Its isoelectric point (pI) was approximately 5.24 (Figure
2). These findings show that there is a possibility that the TA02
polypeptide and the third polypeptide may be phosphorylated
forms ofthe TAO1 polypeptide.
Finally, our present data indicate that expression levels ofTAOI
and TA02 polypeptides correlate with the histopathological differ-
entiation of adenocarcinoma. At present, histopathological diag-
nosis, especially concerning differentiation, is based on subjective
observation by experienced pathologists. If we could succeed in
producing monoclonal antibodies against TAO1 and TA02
polypeptides, quantitative and objective diagnosis ofthe degree of
differentiation ofadenocarcinoma may be realized.
ABBREVIATIONS
CHAPS, 3-[(3-Cholamidopropyl) dimethylammonio]-l-propane-
sulphonate; 2-DE, two-dimensional polyacrylamide gel elec-
trophoresis; pl, isoelectric point; MD adenocarcinoma, moderately
differentiated adenocarcinoma; MW, molecular weight; PMSF,
phenylmethyl sulphonyl fluoride; PD adenocarcinoma, poorly
differentiated adenocarcinoma; SDS, sodium dodecyl sulphate;
WD adenocarcinoma, well-differentiated adenocarcinoma.
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